U.S. markets close in 5 hours 3 minutes
  • S&P 500

    4,286.21
    -10.93 (-0.25%)
     
  • Dow 30

    33,991.20
    +78.76 (+0.23%)
     
  • Nasdaq

    13,018.69
    -109.37 (-0.83%)
     
  • Russell 2000

    2,004.64
    -16.70 (-0.83%)
     
  • Crude Oil

    88.37
    -1.04 (-1.16%)
     
  • Gold

    1,792.70
    -5.40 (-0.30%)
     
  • Silver

    20.15
    -0.12 (-0.60%)
     
  • EUR/USD

    1.0180
    +0.0016 (+0.15%)
     
  • 10-Yr Bond

    2.8490
    +0.0580 (+2.08%)
     
  • GBP/USD

    1.2093
    +0.0035 (+0.29%)
     
  • USD/JPY

    134.3840
    +1.1120 (+0.83%)
     
  • BTC-USD

    23,768.48
    -357.65 (-1.48%)
     
  • CMC Crypto 200

    565.65
    -6.27 (-1.10%)
     
  • FTSE 100

    7,535.57
    +26.42 (+0.35%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So, the natural question for Atomo Diagnostics (ASX:AT1) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Atomo Diagnostics

Does Atomo Diagnostics Have A Long Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In December 2021, Atomo Diagnostics had AU$14m in cash, and was debt-free. In the last year, its cash burn was AU$12m. So it had a cash runway of approximately 14 months from December 2021. Notably, one analyst forecasts that Atomo Diagnostics will break even (at a free cash flow level) in about 2 years. Essentially, that means the company will either reduce its cash burn, or else require more cash. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Well Is Atomo Diagnostics Growing?

At first glance it's a bit worrying to see that Atomo Diagnostics actually boosted its cash burn by 42%, year on year. And we must say we find it concerning that operating revenue dropped 17% over the same period. Considering both these metrics, we're a little concerned about how the company is developing. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Atomo Diagnostics To Raise More Cash For Growth?

Atomo Diagnostics revenue is declining and its cash burn is increasing, so many may be considering its need to raise more cash in the future. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Atomo Diagnostics has a market capitalisation of AU$37m and burnt through AU$12m last year, which is 32% of the company's market value. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution.

So, Should We Worry About Atomo Diagnostics' Cash Burn?

On this analysis of Atomo Diagnostics' cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. One real positive is that at least one analyst is forecasting that the company will reach breakeven. We don't think its cash burn is particularly problematic, but after considering the range of factors in this article, we do think shareholders should be monitoring how it changes over time. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 2 warning signs for Atomo Diagnostics that potential shareholders should take into account before putting money into a stock.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here